

REMARKS

This amendment is provided to amend the specification to recite the relationship of this divisional application to previously filed applications, and to add claims to the patentable subject pursued in this application. No new matter is presented, and the Examiner is kindly requested to enter this amendment.

Respectfully submitted,

Date: 2 May 2001


Valeta A. Gregg, Reg. No. 35,127
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

2025 RELEASE UNDER E.O. 14176

Marked Version Showing Changes Made

6. (Amended) A pharmaceutical composition for [preventing or delaying the onset of a disease having the characteristics of] treating or ameliorating type 1 diabetes [or for ameliorating an early stage thereof in a mammal at risk of developing said disease which composition comprises an effective amount of a hormonally inactive insulin or insulin analogue according to any one of the claims 1 and 2 to 5] comprising a hormonally inactive insulin analogue selected from the group consisting of desA1 human insulin, des(A1-A2) human insulin, des(A1-A3) human insulin, desA21 human insulin, des(B1-B5) human insulin, des(B1-B6) human insulin, des(B24-B30) human insulin, des(B25-B30) human insulin, Gly^{A2} human insulin, Ala^{A2} human insulin, Nle^{A2} human insulin, Thr^{A2} human insulin, Pro^{A2} human insulin, D-allo Ile^{A2} human insulin, Nva^{A3} human insulin, Nle^{A3} human insulin, Leu^{A3} human insulin, Val^{A2},Ile^{A3} human insulin, Abu^{A2},Abu^{A3} human insulin, Gly^{A2},Gly^{A3} human insulin, D-Cys^{A6} human insulin, D-Cys^{A6},D-Cys^{A11} human insulin, Ser^{A6},Ser^{A11},des(A8-A10) human insulin, D-Cys^{A7} human insulin, D-Cys^{A11} human insulin, Leu^{A19} human insulin, Gly^{B6} human insulin, Glu^{B12} human insulin, Asn^{B12} human insulin, Phe^{B12} human insulin, D-Ala^{B12} human insulin, and Asp^{B25} human insulin.